# Dean F. Bajorin

Source: https://onco.cc/people/dean-bajorin/  
OnCo record `dean-bajorin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery.

## Summary

Dean Bajorin was principal investigator of CheckMate 274, the trial showing adjuvant nivolumab improves disease-free survival in muscle-invasive urothelial cancer after radical surgery, the first adjuvant immunotherapy approval in the disease. He developed the Bajorin prognostic model for metastatic urothelial cancer and led decades of chemotherapy trials at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: urothelial; adjuvant; immunotherapy
- Role: Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center
- Specialisms: Urothelial cancer; Adjuvant immunotherapy; Chemotherapy; Prognostic models

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Bajorin%20DF%5BAuthor%5D%20urothelial%20nivolumab

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [CheckMate 274](https://onco.cc/trials/checkmate-274/)

---
JSON: https://onco.cc/api/v1/entities/dean-bajorin.json